Gregory A.  Demopulos net worth and biography

Gregory Demopulos Biography and Net Worth

CEO of Omeros
Dr. Demopulos founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

What is Gregory A. Demopulos' net worth?

The estimated net worth of Gregory A. Demopulos is at least $426,370.80 as of November 17th, 2023. Dr. Demopulos owns 123,945 shares of Omeros stock worth more than $426,371 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Demopulos may own. Additionally, Dr. Demopulos receives an annual salary of $1,790,000.00 as CEO at Omeros. Learn More about Gregory A. Demopulos' net worth.

How old is Gregory A. Demopulos?

Dr. Demopulos is currently 65 years old. There are 7 older executives and no younger executives at Omeros. Learn More on Gregory A. Demopulos' age.

What is Gregory A. Demopulos' salary?

As the CEO of Omeros Co., Dr. Demopulos earns $1,790,000.00 per year. Learn More on Gregory A. Demopulos' salary.

How do I contact Gregory A. Demopulos?

The corporate mailing address for Dr. Demopulos and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Gregory A. Demopulos' contact information.

Has Gregory A. Demopulos been buying or selling shares of Omeros?

Gregory A. Demopulos has not been actively trading shares of Omeros over the course of the past ninety days. Most recently, on Friday, November 17th, Gregory A. Md Demopulos bought 15,000 shares of Omeros stock. The stock was acquired at an average cost of $1.68 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer now directly owns 123,945 shares of the company's stock, valued at $208,227.60. Learn More on Gregory A. Demopulos' trading history.

Who are Omeros' active insiders?

Omeros' insider roster includes Gregory Demopulos (CEO), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.

Are insiders buying or selling shares of Omeros?

During the last year, Omeros insiders bought shares 2 times. They purchased a total of 25,000 shares worth more than $40,500.00. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 5,000 shares worth more than $32,300.00. The most recent insider tranaction occured on November, 17th when CEO Gregory A Md Demopulos bought 15,000 shares worth more than $25,200.00. Insiders at Omeros own 10.9% of the company. Learn More about insider trades at Omeros.

Information on this page was last updated on 11/17/2023.

Gregory A. Demopulos Insider Trading History at Omeros

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2023Buy15,000$1.68$25,200.00123,945View SEC Filing Icon  
6/17/2021Sell36,857$14.90$549,169.302,063,842View SEC Filing Icon  
6/15/2021Sell36,856$15.02$553,577.122,063,842View SEC Filing Icon  
4/8/2021Sell72,613$17.84$1,295,415.922,064,393View SEC Filing Icon  
12/7/2016Sell306,124$10.66$3,263,281.841,987,025View SEC Filing Icon  
12/6/2016Sell102,040$10.80$1,102,032.001,987,025View SEC Filing Icon  
12/5/2016Sell102,040$10.71$1,092,848.401,987,025View SEC Filing Icon  
12/2/2016Sell306,120$11.58$3,544,869.601,801,381View SEC Filing Icon  
See Full Table

Gregory A. Demopulos Buying and Selling Activity at Omeros

This chart shows Gregory A Md Demopulos's buying and selling at Omeros by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Omeros Company Overview

Omeros logo
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.45
Low: $3.36
High: $3.51

50 Day Range

MA: $3.90
Low: $3.24
High: $4.89

2 Week Range

Now: $3.45
Low: $0.92
High: $7.80

Volume

331,192 shs

Average Volume

593,240 shs

Market Capitalization

$216.90 million

P/E Ratio

10.78

Dividend Yield

N/A

Beta

1.38